Amerikanische Gesellschaft für Hirudotherapie

Loss of ELK1 has differential effects on age-dependent organ fibrosis

Research article published in The international journal of biochemistry & cell biology (2019)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenomik & ProteomikCairns JT et al. · The international journal of biochemistry & cell biology, 2019

Abstract

ETS domain-containing protein-1 (ELK1) is a transcription factor important in regulating αvβ6 integrin expression. αvβ6 integrins activate the profibrotic cytokine Transforming Growth Factor β1 (TGFβ1) and are increased in the alveolar epithelium in idiopathic pulmonary fibrosis (IPF). IPF is a disease associated with aging and therefore we hypothesised that aged animals lacking Elk1 globally would develop spontaneous fibrosis in organs where αvβ6 mediated TGFβ activation has been implicated. Here we identify that Elk1-knockout (Elk1-/0) mice aged to one year developed spontaneous fibrosis in the absence of injury in both the lung and the liver but not in the heart or kidneys. The lungs of Elk1-/0 aged mice demonstrated increased collagen deposition, in particular collagen 3α1, located in small fibrotic foci and thickened alveolar walls. Despite the liver having relatively low global levels of ELK1 expression, Elk1-/0 animals developed hepatosteatosis and fibrosis. The loss of Elk1 also had differential effects on Itgb1, Itgb5 and Itgb6 expression in the four organs potentially explaining the phenotypic differences in these organs. To understand the potential causes of reduced ELK1 in human disease we exposed human lung epithelial cells and murine lung slices to cigarette smoke extract, which lead to reduced ELK1 expression andmay explain the loss of ELK1 in human disease. These data support a fundamental role for ELK1 in protecting against the development of progressive fibrosis via transcriptional regulation of beta integrin subunit genes, and demonstrate that loss of ELK1 can be caused by cigarette smoke.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov't
Indexed MeSH termsAge FactorsAnimalsBronchiFibrosisHumansLungMaleMiceMice, Knockoutets-Domain Protein Elk-1

Zusammenfassung

ETS domain-containing protein-1 (ELK1) is a transcription factor important in regulating v6 integrin expression.

Warum dies für die Hirudotherapie relevant ist

This experimental study investigated the role of the transcription factor ETS domain-containing protein-1 (ELK1) in age-dependent organ fibrosis using Elk1-knockout mice. The researchers found that aged mice lacking Elk1 developed spontaneous fibrosis in the lungs and liver, linking this to the transcriptional regulation of beta integrin subunit genes and exposure to cigarette smoke. The article has no discernible relevance to the American Society of Hirudotherapy, as it does not mention or investigate leeches, hirudotherapy, the leech secretome, or any related anticoagulants. The research is strictly focused on molecular genetics and pulmonary pathology in a mouse model.

Zitation

Loss of ELK1 has differential effects on age-dependent organ fibrosis

Cairns JT et al. · The international journal of biochemistry & cell biology, 2019

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.